New stock news | Baoji Pharmaceutical has submitted documents to the Hong Kong Stock Exchange for the second time this year. Its core products have all entered the late clinical stage or NDA registration stage in China.

According to the Intelligent Financial APP, Shanghai Baoji Pharmaceutical Co., Ltd. (referred to as Baoji Pharmaceutical) submitted an application for listing on the main board of the Hong Kong Stock Exchange on August 21, as disclosed by the Hong Kong Stock Exchange. CITIC Securities and Haitong International are its joint sponsors. This is the company's second application for listing this year.